Microglia cells were treated with MCM from the four melanoma cell lines together with inhibitors for STAT3 (targeting Ser727, but not the Tyr705 residue)—which is downstream to JAK activation, JAK, JNK or MEK/ERK for 3 h. The gene discussed is MAP2K7; the disease is melanoma.